A071102

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

ClinicalTrials.gov Identifier: NCT02152982

Study Background

Trial Description

This randomized phase II/III trial studies how well temozolomide and veliparib work compared to temozolomide alone in treating patients with newly diagnosed glioblastoma multiforme. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether temozolomide is more effective with or without veliparib in treating glioblastoma multiforme.

Arms:

Arm I (Arm B) (temozolomide, veliparib): (Experimental): Patients receive temozolomide PO QD on days 1-5 and veliparib PO BID on days 1-7. Treatment repeats every 28 days for 6 cycles in the absence of disease progression (confirmed progression) or unacceptable toxicity.

Arm II (Arm A) (temozolomide, placebo): (Placebo Comparator): Patients receive temozolomide as in Arm I and placebo PO BID on days 1-7. Treatment repeats every 28 days for 6 cycles in the absence of disease progression (confirmed progression) or unacceptable toxicity.

Objectives:

- PRIMARY OBJECTIVE: I. Test whether the experimental combination of ABT-888 (veliparib) combined with TMZ (temozolomide), compared to the control of placebo combined with TMZ, significantly extends overall survival in newly diagnosed glioblastoma multiforme (GBM) patients with tumor MGMT promoter hypermethylation. SECONDARY OBJECTIVES: I. Test whether the experimental treatment significantly extends progression-free survival.

II. Test whether the experimental treatment improves objective tumor response. III. Test whether the experimental treatment is associated with significantly greater rates of grade 3 or higher adverse events. CORRELATIVE SCIENCE OBJECTIVES: I. Evaluate the utility of dynamic susceptibility contrast (DSC) and diffusion weighted imaging (DWI) magnetic resonance imaging (MRI) techniques in defining time to progression in the setting of a large multi-institutional clinical trial.

III. Test the concordance between site-determined MGMT methylation status and central laboratory determination of MGMT status in cases with local testing.

IV. Evaluate whether genetic or epigenetic alterations in deoxyribonucleic acid (DNA) repair or replication genes are associated with overall survival, progression-free survival, and objective tumor response.

V. Test whether polymorphisms in MGMT, PARP1, or other DNA repair proteins, are associated with overall survival, progression-free survival, objective tumor response, or rates of grade 3 or higher adverse events. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive temozolomide orally (PO) once daily (QD) on days 1-5 and veliparib PO twice daily (BID) on days 1-7. Treatment repeats every 28 days for 6 cycles in the absence of disease progression (confirmed progression) or unacceptable toxicity. ARM II: Patients receive temozolomide as in Arm I and placebo PO BID on days 1-7. Treatment repeats every 28 days for 6 cycles in the absence of disease progression (confirmed progression) or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 3 years, every 6 months for 2 years.

Study Milestones:

Start date: December 15, 2014

Primary Completion Date: December 1, 2021

Publication Information:

Analysis Type: Primary

PubMed ID: 39480453

Citation:

Associated Datasets: NCT02152982-D1-Dataset.csv (patient), NCT02152982-D2-Dataset.csv (adverse_events), NCT02152982-D3-Dataset.csv (lasa)

Dataset Information:

Dataset Name: NCT02152982-D1-Dataset.csv (patient)

Description: Dataset NCT02152982-D1-Dataset.csv (patient) is one of 3 datasets associated with PubMed ID 39480453. This dataset contains data presented in the baseline characteristics table, primary and secondary analysis. NCT02152982-D2 contains adverse event data and NCT02152982-D3 contains patient reported fatigue data.

Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).

Blank values indicate data not applicable or missing, except where otherwise noted.

NCT02152982-D1-Dataset.csv (patient) Data Dictionary:

LABEL	NAME	ELEMENTS	COMMENTS
Race	race	Asian | Black or African American | Unknown/Not Reported/Other | White	
Ethnicity	ethnicity	Hispanic or Latino | Not Hispanic or Latino | Unknown/Not Reported	
Patient ID	DCNTR_ID		
Age (years)	AGE		
Arm	ARM	A: TMZ + Placebo | B: TMZ + Veliparib	
End of Active Treatment Reason	ENDATRSN	Adverse Events/Side Effects/Complications | Death On Study | Disease Progression Before Active Treatment (Intervention) | Disease Progression, Relapse During Active Treatment (Intervention)	

LABEL	NAME	ELEMENTS	COMMENTS
		| Other | Patient Off-Treatment (Intervention) For Other Complicating Disease | Patient Withdrawal/Refusal After Beginning Protocol Therapy (Intervention) | Patient Withdrawal/Refusal Prior To Beginning Protocol Therapy (Intervention) | Treatment Completed Per Protocol	
Ineligible	INELIG	Yes	Blanks indicate patient is eligible
Extent of resection	extsurgc	Gross total resection | Subtotal resection or biopsy	
Planned concomitant use of Optune device	optune_c	No | Yes	
ECOG Performance Status	ps_bsl	0 or 1 | 2	
Side of lesion	SIDE	Bilateral | Left | Midline | Right	
Tumor Location	location	Frontal | Multiple Locations | Occipital | Other | Parietal | Temporal | Thalamus	
OS Status (Alive/Dead)	os_stat	Censor | Event	
Progression Free Survival Status	pfs_stat	Censor | Event	

LABEL	NAME	ELEMENTS	COMMENTS
OS Time (days)	os_time		
Progression Free Survival Time (days)	pfs_time		
Gender	gender	Female | Male	
Phase	phase	Phase 2 | Phase 3	
Enrolled after amendment 3 (Optune/TTF allowed)	amend3	No | Yes	
Time from registration to end of active treatment (days)	time_on_study		
Treatment Status	treated	Did not receive any treatment | Received at least one dose of treatment	
Optune (TTF) Administered	opt_any	No | Yes	
Measurable Disease Status	measurable_disease	0=No | 1=Yes	
Best Response (measurable disease only)	best_response_md	Confirmed PD | CR | Not evaluated | PR | Preliminary PD | Pseudo-progression | SD	
Response to therapy (measurable disease only)	responder_md	CR/PR | No Response	
Pseudoprogression Observed	pseudoprog	No | Yes	

LABEL	NAME	ELEMENTS	COMMENTS
Off protocol TMZ administered	prot_tx_plus	0=No additional TMZ | 1=TMZ administered after cycle 6	